Genetic and environmental susceptibility to non-alcoholic fatty liver disease

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 255-260

  Day, Christopher Paul ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Free fatty acid; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN II; ANGIOTENSINOGEN; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE IA; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD14 ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; ENDOTOXIN; FATTY ACID; KRUPPEL LIKE FACTOR 6; MANGANESE SUPEROXIDE DISMUTASE; PATATIN LIKE PHOSPHOLIPASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; PHOSPHOLIPASE; PROTEIN DDX5; STROMELYSIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CYTOKINE RELEASE; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; FATTY LIVER; FRAMESHIFT MUTATION; GENE IDENTIFICATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LIVER DISEASE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

DISEASE SUSCEPTIBILITY; FATTY LIVER; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIVER; OXIDATIVE STRESS;

EID: 77952563587     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282098     Document Type: Review

References (40)

1. Neuschwander-Tetri B, Caldwell S: Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202-1219.
2. Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-1110.
3. Dixon J, Bhathal P, O'Brian P: Non-alcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
4. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008;14:72-81.
5. Day CP: Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:663-678.
6. Day CP: From fat to inflammation. Gastroenterology 2006;130: 207-210,
7. Hui J, Hodge A, Farrell G, Kench J, Kriketos A, George J: Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
8. Dunn W, Xu R, Schwimmer JB: Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008;47:1947-1954.
9. Musso G, Gambino R, De Michieli F, et al: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-916.
10. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG: The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-211.
11. Miele L, Valenza V, La Torre G, et al: Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-1887.
12. Singh H, Pollock R, Uhanova J, Kryger M, Hawkins K, Minuk G: Symptoms of obstructive sleep apnoea in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2005;50:2338-2343.
13. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Alterio A, Tiribelli C, Agostoni C: A protective effect of breastfeeding on progression of non-alcoholic fatty liver disease. Arch Dis Child 2009;94:801-805.
14. Schwimmer JB, Celedon MA, Lavine JE, et al: Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009;136:1585-1592.
15. Makkonen J, Pietilainen KH, Rissanen A, Kaprio J, Yki-Jarvinen H: Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol 2009;50:1035-1042.
16. Struben VMD, Hespenheide EE, Caldwell SH: Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Medicine 2000;108:9-13.
17. Willner I, Waters B, Patil S, Reuben A, Morelli J, Riely CA: Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-2961.
18. Browning JD, Kumar KS, Saboorian MH, Theile DL: Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004;99:292-298.
19. Caldwell SH, Harris DM, Patrie JT, Hespen-heide EE: Is NASH underdiagnosed among African Americans? Am J Gastroenterol 2002;97:1496-1500.
20. Yamaguchi K, Yang L, McCall S, Huang J, Yu X, Pandey S, Bhanot S, et al: Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45:1366-1374.
21. Romeo S, Kozlitina J, Xing C, et al: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:14 61-1465.
22. Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A, Bergholm R, et al: A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009;52:1056-1060.
23. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ: A non-synonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009;50:2111-2116.
24. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA: Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010;42:21-23.
25. Namikawa C, Shu-Ping Z, Vyselaar J, et al: Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in nonalcoholic steatohepatitis. J Hepatol 2004;40:781-786.
26. Bernard S, Touzet S, Personne I, Lapras V, Bondon P, Berthezene F, Moulin P: Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000;43:995-999.
27. Dong H, Wang J, Li C, et al: The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J Hepatol 2007;46:915-920.
28. George D, Goldwurm S, Macdonald G, et al: Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318.
29. Nelson J, Bhattacharya R, Lindor K, et al: HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 2007;46:723-729.
30. Bugianesi E, Manzini P, D'Antico S, et al: Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:179-187. (Pubitemid 38461480)
31. Saksena S, Daly A, Leathart J, Day C: Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2003;38(suppl 2):47.
32. Nobili V, Daly A, Al-Serri A, et al: The mitochondrial superoxide dismutase 2 (SOD2) targeting sequence polymorphism is associated with fibrotic NAFLD: consistent evidence from case-control and intra-familial allelic association studies. Hepatology 2007;46:760A.
33. * in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999;20:976-983.
34. Day C, Leathart J, McTernan P, Mathew C, Daly A: Genetic evidence for a role of gut flora in the pathogenesis of NASH in humans. Hepatology 2006;44(suppl 1):261A.
35. Valenti L, Fracanzani A, Dongiovanni P, et al: Tumour necrosis factor promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002;122:272-280.
36. Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K: Influence of TNF gene polymorphism in Japanese patients with NASH and simple steatosis. J Hepatol 2007;46:1104-1110.
37. Bataller R, North K, Brenner D: Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37:493-503.
38. Dixon J, Bhathal P, Jonsson J, Dixon A, Powell E, O'Brien PE: Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 2003;39:967-971.
39. Yoneda M, Hotta K, Nozaki Y, et al: Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int 2009;29:1078-1085.
40. Miele L, Beale G, Patman G, et al: The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008;135:282-291, e281.